Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Films for the medical and electronics sectors and industrial materials for semiconductor wafer transport and manufacturing processes performed strongly, while sales of shoes and vehicle materials for China declined. Profit improvement was also supported by reductions in raw material and energy costs through production consolidation, cost-reduction initiatives, and company-wide expense controls.
No applicable matters. The filing states, "There are no applicable matters."
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥81,802 million (YoY +3.4%) |
| Operating profit | ¥2,972 million |
| Ordinary income | ¥3,919 million |
| Profit attributable to owners of the parent | ¥2,116 million (YoY +394.7%) |
| Net income per share | ¥154.87 |
| Operating Margin | 3.6% |
| Equity ratio | End of the current fiscal period 51.8% / End of previous period 49.5% |
| Total assets | ¥83,628 million |
| Net assets | ¥43,282 million |
| Cash flows from operating activities | ¥2,639 million |
| Cash flows from investing activities | ¥-2,862 million |
| Cash flows from financing activities | ¥2,146 million |
| Cash and cash equivalents at end of period | ¥8,746 million |
| Full-year earnings forecast | Net Sales ¥82,500 million (YoY +0.9%) / Operating profit ¥2,200 million (YoY -26.0%) / Ordinary income ¥2,000 million (YoY -49.0%) / Profit attributable to owners of the parent ¥1,300 million (YoY -38.6%) |
| Annual Dividend Forecast | ¥40 → ¥30（-25.0%） |
| Payout ratio | 31.5% |
| Segment revenue | Business Division 1 ¥49,910 million (YoY +7.8%), Business Division 2 ¥22,964 million (YoY +1.2%), Shoes BU ¥8,928 million (YoY -11.7%) |
| Segment profit | Business Division 1 ¥3,287 million (YoY +228.0%), Business Division 2 ¥2,390 million (YoY +26.9%), Shoes BU ¥-321 million |
| Regional sales | ¥60,373 million, ¥10,773 million, ¥10,655 million |
| Depreciation and amortization | ¥2,739 million |
| Impairment loss | ¥905 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥14 million / Extraordinary loss Impairment Losses ¥905 million, Loss on Disposal of Fixed Assets ¥79 million, Impairment loss on investment securities ¥1 million |
| Disclosure regarding the going concern assumption | No applicable matters. The filing states, "There are no applicable matters." |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 14,562,714 shares |
| Treasury Shares at Period-End | 896,793 shares |
| Factors Behind Changes in Business Performance | Films for the medical and electronics sectors and industrial materials for semiconductor wafer transport and manufacturing processes performed strongly, while sales of shoes and vehicle materials for China declined. Profit improvement was also supported by reductions in raw material and energy costs through production consolidation, cost-reduction initiatives, and company-wide expense controls. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Profit improved due to strong performance in films for the medical sector and industrial materials related to semiconductors, as well as reductions in raw material and energy costs through production consolidation and expense controls. The forecast for the next fiscal year incorporates proactive investment in human capital management and digital transformation, along with foreign exchange fluctuation risks. The company is also concerned about the impact of the situation in the Middle East, crude oil and naphtha prices, energy and logistics costs, and the supply chain.